Literature DB >> 12232845

Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994-1998.

Janice K Louie1, Ling Chin Hsu, Dennis H Osmond, Mitchell H Katz, Sandra K Schwarcz.   

Abstract

To understand recent temporal trends in acquired immunodeficiency syndrome (AIDS) mortality in the era of highly active antiretroviral therapy (HAART), trends in causes of death among persons with AIDS in San Francisco who died between 1994 and 1998 were analyzed. Among 5234 deaths, the mortality rate for human immunodeficiency virus (HIV)-related or AIDS-related deaths declined after 1995 (P<.01), whereas the mortality rate for non-HIV- or non-AIDS-related deaths remained stable. The proportion of deaths of persons with AIDS associated with septicemia, non-AIDS-defining malignancy, chronic liver disease, viral hepatitis, overdose, obstructive lung disease, coronary artery disease, and pancreatitis increased (P<.05). The standardized mortality ratio was high for these causes in both pre- and post-HAART periods, except for pancreatitis, a possible complication of HAART, which demonstrated an increasing standardized mortality ratio trend after 1996. With increasing AIDS survival, prevention of chronic diseases, assessment of long-term toxicity from HAART, and surveillance for additional causes of mortality will become increasingly important.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12232845     DOI: 10.1086/343862

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  39 in total

1.  Decreased Lung Function and All-Cause Mortality in HIV-infected Individuals.

Authors:  Matthew R Gingo; Mehdi Nouraie; Cathy J Kessinger; Ruth M Greenblatt; Laurence Huang; Eric C Kleerup; Lawrence Kingsley; Deborah K McMahon; Alison Morris
Journal:  Ann Am Thorac Soc       Date:  2018-02

2.  Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study.

Authors:  Nancy Crum-Cianflone; Katherine Huppler Hullsiek; Vincent Marconi; Amy Weintrob; Anuradha Ganesan; R Vincent Barthel; Susan Fraser; Brian K Agan; Scott Wegner
Journal:  AIDS       Date:  2009-01-02       Impact factor: 4.177

3.  Estimating the prevalence of injection drug use among black and white adults in large U.S. metropolitan areas over time (1992--2002): estimation methods and prevalence trends.

Authors:  Hannah L F Cooper; Joanne E Brady; Samuel R Friedman; Barbara Tempalski; Karla Gostnell; Peter L Flom
Journal:  J Urban Health       Date:  2008-08-16       Impact factor: 3.671

4.  Trimethoprim-sulfamethoxazole treatment does not reverse obstructive pulmonary changes in pneumocystis-colonized nonhuman primates with SHIV infection.

Authors:  Heather M Kling; Timothy W Shipley; Siobhan Guyach; Rebecca Tarantelli; Alison Morris; Karen A Norris
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-01       Impact factor: 3.731

Review 5.  Lung cancer in HIV infected patients: facts, questions and challenges.

Authors:  J Cadranel; D Garfield; A Lavolé; M Wislez; B Milleron; C Mayaud
Journal:  Thorax       Date:  2006-11       Impact factor: 9.139

6.  Contributors to diffusion impairment in HIV-infected persons.

Authors:  Matthew R Gingo; Jiayan He; Catherine Wittman; Carl Fuhrman; Joseph K Leader; Cathy Kessinger; Lorrie Lucht; William A Slivka; Yingze Zhang; Deborah K McMahon; Frank C Sciurba; Alison Morris
Journal:  Eur Respir J       Date:  2013-02-21       Impact factor: 16.671

7.  Incidence of noninfectious conditions in perinatally HIV-infected children and adolescents in the HAART era.

Authors:  Sharon A Nachman; Miriam Chernoff; Philimon Gona; Russell B Van Dyke; Wayne M Dankner; George R Seage; James Oleske; Paige L Williams
Journal:  Arch Pediatr Adolesc Med       Date:  2009-02

Review 8.  Pathogenesis of HIV and the lung.

Authors:  Matthew R Gingo; Alison Morris
Journal:  Curr HIV/AIDS Rep       Date:  2013-03       Impact factor: 5.071

9.  Hepatitis C virus infection in San Francisco's HIV-infected urban poor.

Authors:  Christopher S Hall; Edwin D Charlebois; Judith A Hahn; Andrew R Moss; David R Bangsberg
Journal:  J Gen Intern Med       Date:  2004-04       Impact factor: 5.128

Review 10.  [Impact of prophylactic HPV vaccines on dermatology and venereology].

Authors:  G Gross
Journal:  Hautarzt       Date:  2007-06       Impact factor: 0.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.